Flt-3L-Ig (hum/hum)
Based on 1 Customer Validation
Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation.
For research use only. We do not sell to patients.
- Purity : 98%
- Molecular Weight:86.938 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Species Reactivity
Human
IC50 & Target
[1]|
IL-2 |
In Vivo
Flt-3L-Ig (hum/hum) (10 μg; i.p.; on day 0, 2, 4, and 7) increases immune cell populations in BRGSF-HIS mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BRGSF mice (female, 21-22 weeks old, humanized with umbilical cord blood CD34+ cells)[1]
-
Dosage:10 μg per injection
-
Administration:i.p.; four times on days 0, 2, 4, and 7 (every 2-3 days)
-
Result:Increased OKT3-induced serum levels of IL-2, CCL2, and CXCL10.
Enhanced OKT3-induced body weight loss, reaching a 13-15% reduction from baseline at 48h post-OKT3.
Induced a significant temperature drop, a ~4-6% reduction from baseline at 24h post-OKT3, an effect not seen in non-boosted mice.
Amplified OKT3-induced depletion of plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs), and monocytes/macrophages.
Enhanced OKT3-induced activation of pDCs, cDCs, and neutrophils, measured by increased percentages of CD86+, CD80+, and CD86+/CD80+ cells in these populations.
Increased absolute and relative numbers of human monocytes/macrophages, pDCs, and cDCs in bone marrow, spleen, and systemic circulation without inducing significant immune cell activation.\nEnabled detection of Blinatumomab-induced CRS features, including significant increases in serum levels of human TNF-α, IL-6, IFN-γ, CCL2, and CXCL10, and a sustained, significant reduction in body temperature at the 5 μg/kg Blinatumomab dose.\nEnabled detection of JNJ-induced CRS features, including dose-dependent increases in serum levels of human CCL5, CCL2, CXCL8, TNF-α, IL-1RA, and IL-10.
Caused significant depletion of monocytes/macrophages and cDCs at 48h post-JNJ injection.
Induced significant increases in the percentage of CD86+ activated monocytes/macrophages and cDCs at 24h post-JNJ injection (at the 20 mg/kg JNJ dose).
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Verified Bioactivity
-
Loaded Flt-3L-Ig (hum/hum) on AHC2 biosensor, can bind FLT3 Protein, Human (T227M, HEK293, His, HY-P75183) with an affinity constant of 2.041E-08 M as determined in BLI assay.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 86.938 kDa
-
Color Colorless to light yellow
-
SMILES
[Flt-3L-Ig (hum/hum)]
-
Synonyms
human Flt3L; hFlt3L
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Contact Hypersensitivity Dermatitis
Contact hypersensitivity (CHS) dermatitis is a T cell-mediated delayed-type (Type IV) immune reaction in which low-molecular-weight haptens applied to the skin bind host proteins to form complete antigens, triggering sensitization followed by a secondary inflammatory response upon re-exposure (elicitation phase), which is commonly quantified by ear swelling as a readout of skin inflammation in murine models. This model is widely used to study allergic contact dermatitis because it is antigen-specific, reproducible, and reflects key immunological events including dendritic cell activation, T cell priming in draining lymph nodes, and effector T cell-driven tissue inflammation. DNFB- and oxazolone-induced CHS models are standard systems for evaluating both acute and chronic T cell-dependent skin inflammation and for testing immunomodulatory interventions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Martin GH, et al. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. Front Immunol. 2024;15:1357716. Published 2024 Feb 7. [Content Brief]
[2]. Christensen PKF, et al. Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity. PLoS One. 2023;18(2):e0281005. Published 2023 Feb 17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Flt-3L-Ig (hum/hum)
- human Flt3L
- hFlt3L
- FLT3
- Interleukin Related
- CCR
- cytokine release syndrome
- human myeloid/dendritic progenitors
- conventional dendritic cells
- human monocytes/macrophages
- plasmacytoid dendritic cells
- BRGSF-HIS mice
- Flk2
- psoriasis-like skin inflammation
- BRGSF mice
- human dendritic cells
- Inhibitor
- inhibitor
- inhibit